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In recent years,  many researchers have emphasized the importance of metabolic syndrome based on 
its increasing prevalence and its adverse prognosis due to associated chronic vascular complications.  
Upstream of a cluster of metabolic and vascular disorders is the accumulation of visceral adipose tis-
sue,  which plays a central role in the pathophysiology.  In the accumulation of adipose tissues,  cell 
cycle regulation is tightly linked to cellular processes such as proliferation,  hypertrophy and apopto-
sis.  In addition,  various cell cycle abnormalities have also been observed in other tissues,  such as 
kidneys and the cardiovascular system,  and they are critically involved in the progression of disease.  
Here,  we discuss cell cycle abnormalities in metabolic syndrome in various tissues.  Furthermore,  we 
describe the role of nuclear receptors in cell growth and survival,  and glucose and lipid metabolism in 
the whole body.  Therapeutic strategies for modulating various cell cycles in metabolic disorders by 
targeting nuclear receptors may overcome obesity and its chronic vascular complications in the 
future.
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ecently,  the population with metabolic syndrome 
has been increasing in Japan and in other devel-
oped and developing countries.  In Japan,  the national 
health survey in 2010 indicated that one-half of males 
and one-ﬁfth of females from 40 to 74 years old meet 
the criteria of metabolic syndrome [1].  The concept 
of metabolic syndrome represents a cluster of athero-
sclerotic vascular risk factors such as hypertension,  
dyslipidemia,  insulin resistance and glucose intoler-
ance,  which ultimately increases the risk of severe 
complications like cardiovascular,  chronic kidney and 
cerebrovascular diseases.  Upstream of the cluster of 
metabolic disorders is the accumulation of visceral 
adipose tissue.  A strategy for preventing the critical 
complications of metabolic syndrome is urgently 
required for public health and social medical cost 
reduction.  To overcome metabolic syndrome and its 
related vascular complications,  new insights into the 
mechanism and the identiﬁcation of therapeutic targets 
are necessary.  In the line of such considerations,  we 
focus on ﬁndings regarding cell cycle regulation in 
metabolic syndrome.  Cell proliferation,  hypertrophy 
and apoptosis are controlled by cell cycle regulation,  
and cell cycle abnormality has been reported in vari-
ous tissues under metabolic syndrome.  In this review,  
we further consider the roles of nuclear receptors in 
the process of hypertrophy,  proliferation and apopto-
sis of the cells and describe the emerging roles of 
modulators of nuclear receptors to control cell cycles 
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in metabolic syndrome.
Cell Cycle Abnormalities in Metabolic 
Syndrome
　 Cell cycle of adipocyte in metabolic syndrome.
The cell cycle abnormalities of adipocytes in obese 
patients have been investigated.  In obesity,  the large 
mass of adipose tissue is developed through an increase 
both in cell size and number.  Various mechanisms 
involved in adipogenesis have been investigated,  
including cell cycle regulators,  transcription factors,  
ligands of nuclear receptors,  and signaling molecules.  
Sakai et al. reported an initial increase in adipocyte 
size followed by an increase in adipocyte number in 
white adipose tissue [2].  They showed that Skp2-
dependent ubiquitination of p27Kip1 led to cell cycle 
progression,  followed by an increase in the number of 
adipocytes during the development of obesity.  p21Cip1 
is also major cyclin-dependent kinase inhibitor and is 
associated with G1 cell cycle arrest.  Naaz et al. 
reported that both p27Kip1 and p21Cip1 deﬁciency pro-
duces adipocyte hyperplasia and obesity [3].  In con-
trast to that report,  Inoue et al. demonstrated that 
p21Cip1 is induced during adipocyte diﬀerentiation,  and 
promotes adipocyte hypertrophy and obesity-induced 
insulin resistance [4].  In addition,  3T3-L1 ﬁbroblasts 
with deletion of p21Cip1 or embryonic ﬁbroblast from 
p21-/- mice impaired adipocyte diﬀerentiation,  result-
ing in smaller adipocytes [4].  Thus,  the regulation of 
adipocyte size and number may be quite complex.
　 Another important cell cycle regulator,  p53,  is 
well-known as a tumor suppressor gene,  and its bio-
logical role in adipocyte diﬀerentiation has also been 
investigated.  Upon DNA damage,  the activation of p53 
as the ʻGuardian of the Genomeʼ induces cell cycle 
arrest or removal of damaged cells through apoptosis.  
In adipocytes,  p53 blocks clonal expansion and cell 
cycle progression rather than inducing apoptosis,  and 
p53 represents a negative regulator for adipogenesis 
[5].  However,  in later stages of adipocyte matura-
tion,  Bazuine et al. hypothesized that p53 protects 
adipocytes from reactive oxygen species and lipotoxic-
ity induced cell damages by up-regulating cytoprotec-
tive genes to achieve conversion to large lipid-laden 
adipocytes [6].  In the setting of obesity in vivo,  the 
increased expression of p53 in adipose tissues is 
critically involved in the development of senescence-
like changes including increased β-galactosidase 
activities and proinﬂammatory cytokines,  which are 
ultimately linked to the development of insulin resis-
tance [7].  Collectively,  the involvement of cell cycle 
regulators in obesity is somewhat complex,  depending,  
as has been shown,  upon the stage of adipocyte dif-
ferentiation in vitro and upon the animal model used for 
in vivo experiments; thus,  further characterization of 
cell cycle regulators in metabolic syndrome is required 
in future studies.
　 Cell cycles of kidney cells in diabetic neph-
ropathy. The cell cycle of kidney cells had been 
well-investigated in diabetic nephropathy.  Renal hyper-
trophy is one of the earliest abnormalities of diabetic 
nephropathy,  and is the beginning of later irreversible 
structural changes,  such as glomerulosclerosis and 
tubulointerstitial ﬁbrosis [8].  Hyperglycemia increases 
the expression of p21Cip1 and p27Kip1 through a TGF-β 
dependent mechanism,  which halts cell cycle at the G1 
stage (Fig.  1).  In parallel,  when de novo protein syn-
thesis increases,  extracellular matrix protein accumu-
lation occurs,  and consequently the glomeruli become 
hypertrophic [9].  Cell-cycle abnormalities of glomer-
ular cells,  such as mesangial cells,  podocytes and 
endothelial cells,  contribute to the morphological and 
physiological change of glomeruli.  Similar to glomer-
ular cells,  the hyperglycemia-induced up-regulation of 
angiotensin II,  TGF-β and cyclin-dependent kinase 
inhibitors such as p16INK4 and p27Kip1 cause cell-cycle 
arrest and hypertrophy of tubular cells,  i.e.  a senes-
cence-like phenotype [10].  Unlike glomerular cells,  
however,  a diabetic environment also increases the 
apoptosis of tubular cells and results in progression of 
tubular atrophy.  The apoptosis is associated with 
increased expression of Bax and reduced expression 
of bcl-2,  while up-regulation of p27Kip1 and p21Cip1 has 
been reported to limit the degree of apoptosis in 
tubular cells [8,  10].  Thus,  the hypertrophy and 
atrophy of tubules are regulated in a yin and yang 
manner and the cycle regulators determine whether 
the cells exit the cell cycle in the late G1 phase to 
apoptosis or remain in the G1 phase [8].
　 Cell cycle abnormalities of the cardiovascu-
lar system. In metabolic syndrome,  endothelial 
dysfunction gradually and insidiously progresses prior 
to the development of diabetes.  Hyperinsulinemia,  
postprandial hyperglycemia,  reactive oxygen species 
and hypertension assault endothelial cells and promote 
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apoptosis.  Zhong et al. showed that high glucose 
increased the number of senescent cells,  inhibited 
telomerase activity,  increased the proportion of cells 
in the G0/G1 phase,  reduced the proportion in the S 
phase,  and decreased NO synthesis [11].  The abnor-
mal proliferation of vascular smooth muscle cells 
(VSMC) is a key feature of the development of athero-
sclerosis and subsequent cardiovascular complications.  
Hyperglycemia,  growth factors,  and cytokines such as 
TNF-α trigger a mitogenic response,  resulting in the 
activation of cell cycle progression and VSMC prolif-
eration [12,  13].  Cardiomyocytes withdraw from the 
cell cycle and initiate hypertrophic growth soon after 
birth in mammals,  and thus,  a loss of cardiomyocytes 
without replication causes cardiac dysfunction.  Among 
various diabetes-associated cardiovascular complica-
tions,  diabetic cardiomyopathy presents heart failure 
without evidence of hypertension,  coronary artery 
disease,  valvular or congenital heart disease.  The 
mechanism of diabetic cardiomyopathy is multifacto-
rial,  involving autonomic dysfunction,  metabolic 
derangements,  abnormalities in ion homeostasis,  gly-
cation of interstitial proteins such as collagen,  and 
interstitial ﬁbrosis [14].  In an in vivo study,  the 
expression of p21Cip1 and 14-3-3 σ,  which are activated 
via p53 function,  trigger cell-cycle arrest and DNA 
repair,  preventing replication of mutated DNA and 
increasing the stress resistance of heart tissue,  at 
least in early diabetes.  However,  the double cell-cycle 
arrest at G1 and G2 ultimately inhibits the replication 
of cells,  and leads to tissue degeneration in the dia-
betic myocardium in later diabetes [15].
　 Cell cycle abnormalities of cancer cells in 
metabolic syndrome. Elevated body-mass index 
(BMI) is associated with the risk of common cancers in 
adults [16].  The mechanisms have not been fully 
elucidated; however,  the insulin and insulin-like growth 
factor (IGF) axis,  sex steroids,  and adipokines have 
been investigated as candidates for cancer growth in 
obesity [17].  Serum leptin levels were elevated in 
obese patients and leptin was reported to up-regulate 
cdk2 and cyclin D1 and accelerate cell cycle progres-
sion and cell proliferation in various cancer cell lines 
[18].  For example,  leptin-induced cell-cycle progres-
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Fig. 1　 Cell cycle abnormality in diabetic nephropathy.  Erk,  extracellular-signal-regulated kinase; CDK,  cyclin dependent 
kinase; Bcl-2,  B cell lymphoma-2; TGF-β1,  transforming growth factor-β1.
sion and proliferation of breast cancer cell lines were 
associated with the enhanced expression of c-myc and 
cylcin D1 [18].  In the Bcl2-negative cell line,  ZR-75-
1,  it was reported that leptin-induced cell prolifera-
tion is associated with inhibition of p53 and p21Cip1 
[19].  Although leptin is regarded as a pro-carcino-
genic adipokine,  the treatment of a breast cancer cell 
line with leptin enhanced the antiproliferative action 
of cAMP-elevating agents and induced apoptosis.  Such 
leptin-induced apoptosis is accompanied by the decrease 
of cyclin D1 and the increase of p27Kip1,  leading to cell 
cycle arrest at the G1 phase,  and the combination of 
leptin and cAMP-elevating agents may be beneﬁcial 
for the treatment of cancers [20].  Adiponectin is also 
secreted from adipose tissues,  and it stimulates phos-
phorylation of the serine/threonine kinase AMP-
activated protein kinase (AMPK).  AMPK is known to 
increase the expression of p21Cip1,  p27Kip1 and p53.  In 
breast cancer cells,  these cell cycle regulations by 
adiponectin are one of signaling pathways of anti-car-
cinogenic action [18].
Nuclear Receptors and Cell Cycles in Metabolic 
Syndrome
　 Nuclear receptors (NRs) are transcription factors 
that act as intracellular receptors for endocrine hor-
mones and dietary lipids [21],  and play an important 
role for regulating gene expression.  NRs possess 
characteristic structures,  which include N-terminal 
activation function 1 (AF1),  DNA binding,  ligand 
binding,  and C-terminal AF2 domains.  NRs bind to 
speciﬁc DNA sequence elements,  namely,  a consensus 
sequence (AGGTCA) that is constituted as a single 
element or as 2 tandem elements in a direct,  everted 
or inverted repeat.  Such a consensus sequence per-
mits NR binding as monomers,  homodimers or het-
erodimers.  In mammalian species,  there are 48 nuclear 
receptor genes.  Peroxisome proliferator-activated 
receptor (PPAR),  retinoid X receptor (RXR),  liver 
X receptor (LXR),  farnesoid X receptor (FXR) and 
thyroid hormone receptor (TR) are well-known regula-
tors of glucose and lipid metabolism [21].  The retin-
oid acid receptor (RAR) functions as a heterodimer 
with RXR to regulate cell growth and survival [22].
　 PPARs are major NRs in the biology of metabolic 
syndrome,  because they are associated with glucose 
and lipid metabolism,  adipogenesis,  and the inﬂamma-
tory cascade [23].  There are three subtypes of 
PPARs: PPARα,  PPARγ and PPARδ.  The tissue 
distribution and physiological function of the three 
subtypes are diﬀerent.  For example,  PPARα locates 
in the liver,  heart,  muscle and kidney and plays a role 
for fatty oxidation; PPARγ is found in adipose tissue,  
macrophages and muscles and participates in adipogen-
esis and lipid storage; and PPARδ is ubiquitously 
expressed and plays a role in fatty acid oxidation and 
energy expenditure.  After the ligands bind to PPARs,  
the PPARs heterodimerize with RXR,  involving the 
detachment of corepressors,  recruitment of coactiva-
tors,  and subsequent binding to a PPAR response 
element (PPRE) on DNA that initiates the transcrip-
tion of responsive genes.  The G0/G1 switch gene 2 
(G0S2) is one of direct PPARγ target genes with a 
functional PPRE in its promoter [24].  G0S2 regu-
lates the cell cycle,  and the expression of G0S2 is 
associated with growth arrest,  which is required for 
3T3-L1 adipogenesis.  In addition,  G0S2 inhibits 
adipose triglyceride lipase activity and diminishes the 
rate of lipolysis in adipocytes.
　 In RXRs,  there are 3 subtypes: RXRα,  RXRβ and 
RXRγ.  RXRα is expressed in the liver,  kidney,  
spleen,  placenta,  and the epidermis; RXRβ 
ubiquitously; and RXRγ in skeletal muscle and car-
diac muscle,  the anterior pituitary,  and to a lesser 
extent the brain [25].  A RXR knockout model indi-
cated that RXR has various physiological functions.  
RXRα deﬁciency in adipose tissue results in inhibition 
of preadipocyte diﬀerentiation and resistance to obe-
sity.  Loss of RXRα in the liver perturbs multiple 
metabolic pathways mediated by LXRα,  PPARα,  
constitutive androstane receptor β,  pregnane X 
receptor and FXR.  RXRs play roles in diverse physi-
ological processes including cell proliferation,  diﬀer-
entiation,  and apoptosis and metabolism; therefore,  
RXR isotypes have been referred to as master regula-
tors.  On the promoter region of p21Cip1,  there is a 
binding site of RAR/RXR,  and retinoids are thought 
to activate transcription of p21Cip1.  Collectively,  nuclear 
receptors are involved in various central biological 
mechanisms such as development,  metabolism,  cell 
growth,  diﬀerentiation,  and immunity [26,  27].  
Nuclear receptors,  such as PPARs,  RXRs and 
RARs,  control cell cycles through regulating the 
expression of cell cycle-associated genes,  and modu-
late cell proliferation,  apoptosis and hypertrophy.
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Nuclear Receptors Modulator in Metabolic 
Syndrome
　 In a clinical setting,  nuclear receptor modulators 
are widely prescribed in the treatment for dyslipi-
demia and diabetes in patients with metabolic 
syndrome.  For example,  thiazolidinediones (TZDs),  
which are ligands for PPARγ,  are used as insulin 
sensitizers for type 2 diabetes and fatty liver.  TZDs 
are implicated in apoptosis,  cell proliferation,  and 
cell-cycle regulation.  In diabetic nephropathy,  piogli-
tazone,  one of the TZDs,  inhibited cell hypertrophy 
and reversed high glucose-induced G1-phase cell cycle 
arrest,  i.e.  increased the G0/G1 phase and decreased 
the S and G2 phases.  Pioglitazone suppressed high 
glucose-induced phosphorylation of p44/42 mitogen-
activated protein kinase and reduced Bcl-2 and p27Kip1 
protein levels in glomeruli [9].  However,  pioglita-
zone promotes adipogenesis and obesity.  Pioglitazone 
increased the M＋late M population and the M＋late 
M/G0＋G1 ratio,  indicating that pioglitazone increased 
proliferation activities by completing the cell cycle 
[28].  Recently,  pioglitazone has received attention 
for its oncogenic potency in bladder cancer.  Meta-
analysis revealed that the evidence is limited and the 
usage of pioglitazone is not prohibited in many coun-
tries except France [29].
　 Fibrates,  PPARα agonists,  are mainly used as 
hypolipidemic drugs.  In the Fenoﬁbrate Intervention 
in Event Lowering in Diabetes (FIELD) study,  feno-
ﬁbrate treatment signiﬁcantly reduced diabetic retin-
opathy and suppressed albuminuria progression [30].  
In addition,  it was reported that fenoﬁbrate reduced 
not only microvasuclar complications but also macro-
vascular complications.  However,  in rodent models,  
one may concern about the potency of hepatocellular 
carcinoma by ﬁbrate through modulation of cell-cycle 
regulatory genes by PPARα,  i.e.  up-regulation of 
mRNA and protein for cyclin-dependent kinase (CDK)-1,  
CDK-4 and c-myc.  However,  in clinical results from 
humans,  there is no increase in the incidence of hepa-
tocellular carcinoma associated with the use of ﬁbrates.  
This discrepancy derives from structural diﬀerences 
between human and mouse PPARα and from diﬀer-
ences in the expression levels of PPARα in the liver.  
The expression levels of PPARα may be suﬃcient for 
humans to receive beneﬁcial eﬀects of the drugs;  
however,  they are low enough to avoid the activation 
of the genes responsible for the hepatocarcinogenic 
eﬀect of ﬁbrates [31].
Conclusion and Future Directions
　 Nuclear receptor modulators provide diverse ben-
eﬁcial eﬀects such as insulin-sensitizing action,  the 
correction of dyslipidemia,  and the prevention of 
micro- and macro-angiopathies by modulating cell-cycle 
abnormalities in metabolic syndrome.  In clinical set-
ting,  TZDs and ﬁbrates are used as therapeutic 
modalities for lipid and glucose metabolic 
abnormalities; however,  the adverse eﬀects of TZDs 
on edema,  osteoporosis,  obesity,  and oncogenesis of 
the urinary bladder and the deleterious eﬀects of 
ﬁbrates on renal function are also concerns.  The dark 
side of TZDs and ﬁbrates may also derive from the 
modulation of cell cycle,  such as the increased number 
of newly developed adipocytes and the subsequent 
expansion of adipose tissues by TZDs.  In future 
development of nuclear receptor modulators,  dual 
agonists targeting PPARα and PPARγ,  and PPAR 
pan-agonists should be carefully screened to avoid 
unexpected adverse eﬀects,  since nuclear receptors 
regulate fundamental biological processes of the cells,  
such as the cell cycle.
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